Stock PHARM PHARMING GROUP N.V.
Add to a list
To use this feature you must be a member
Log inSign up

Pharming Group N.V. Stock

Equities

PHARM

NL0010391025

Pharmaceuticals

Market Closed - Euronext Amsterdam
Other stock markets
 11:35:15 2024-06-05 am EDT 		After market 02:46:18 pm
0.808 EUR +2.54% Intraday chart for Pharming Group N.V. 0.811 +0.37%
May. 31 Pharming Group Flags Delay in EU Review of Rare Immunodeficiency Drug MT
May. 30 Pharming Group N.V. Provides Update on Ongoing Regulatory Review of Leniolisib for the Treatment of Apds in the European Union CI

Financials

Sales 2024 * 265M 288M Sales 2025 * 300M 326M Capitalization 531M 576M
Net income 2024 * -10M -10.86M Net income 2025 * 3M 3.26M EV / Sales 2024 * 1.67 x
Net cash position 2024 * 87.09M 94.6M Net cash position 2025 * 107M 116M EV / Sales 2025 * 1.41 x
P/E ratio 2024 *
-49.3 x
P/E ratio 2025 *
-197 x
Employees 382
Yield 2024 *
-
Yield 2025 *
-
Free-Float 97.65%
More Fundamentals * Assessed data

Chart Pharming Group N.V.

Dynamic Chart

Latest news about Pharming Group N.V.

Pharming Group Flags Delay in EU Review of Rare Immunodeficiency Drug MT
Pharming Group N.V. Provides Update on Ongoing Regulatory Review of Leniolisib for the Treatment of Apds in the European Union CI
Transcript : Pharming Group N.V. - Shareholder/Analyst Call
Transcript : Pharming Group N.V., Q1 2024 Earnings Call, May 08, 2024
Pharming Group N.V. Provides Revenue Guidance for 2024 CI
Pharming Group N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Pharming Group to Buy Back EUR123 Million of Bonds due 2025 MT
Pharming Group to Issue EUR100 Million Convertible Bonds, Repurchase EUR125 Million Bonds MT
Pharming Group N.V. announced that it expects to receive ?100 million in funding CI
Pharming Group N.V. Announces Completion of Enrollment in Pediatric Clinical Trial of Leniolisib CI
Pharming Group Finishes Enrolling Patients for Phase 3 Pediatric Testing of its Treatment for Rare Auto-Immune Disorder MT
Pharming Group N.V. Provides Earnings Guidance for the Year 2024 CI
Pharming Group Seeks Acquisitions CI
Transcript : Pharming Group N.V., Q4 2023 Earnings Call, Mar 14, 2024
Pharming Group N.V. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
More news

Latest transcript on Pharming Group N.V.

Logo Pharming Group N.V.
Pharming Group N.V. - Shareholder/Analyst Call
More transcripts

Analyst Recommendations on Pharming Group N.V.

RBC Raises Price Target on Pharming Group to EUR2.10 From EUR1.95, Keeps Outperform Rating MT
Oppenheimer Adjusts Pharming Group Price Target to $40 From $36, Maintains Outperform Rating MT
Oppenheimer Adjusts Pharming Group's Price Target to $36 From $43, Maintains Outperform Rating MT
Van Leeuwenhoeck issues research note on Pharming (PHAR.AS): Turning the Page PU
More recommendations

Press releases Pharming Group N.V.

Pharming N : Jefferies Healthcare Conference Presentation June 5 6, 2024 PU
Pharming Group to participate in June investor conferences GL
Pharming N : Group provides update on ongoing regulatory review of leniolisib for the treatment of APDS in the European Union - Form 6-K PU
Pharming Group provides update on ongoing regulatory review of leniolisib for the treatment of APDS in the European Union GL
Pharming N : Physical Settlement Notice 2029 Convertible Bonds PU
More press releases

News in other languages on Pharming Group N.V.

Tegenslag bij EMA resulteert in tijdverlies voor Pharming
Europese goedkeuring voor leniolisib van Pharming loopt vertraging op
Jaarvergadering Pharming akkoord met alle agendapunten
Beursagenda: Nederlandse bedrijven
Beursagenda: Nederlandse bedrijven
More news

Quotes and Performance

1 day+2.54%
1 week-0.25%
Current month-1.52%
1 month-10.22%
3 months-19.52%
6 months-25.19%
Current year-21.63%
More quotes

Highs and lows

1 week
0.72
Extreme 0.722
0.83
1 month
0.72
Extreme 0.722
0.91
Current year
0.72
Extreme 0.722
1.22
1 year
0.72
Extreme 0.722
1.31
3 years
0.66
Extreme 0.6576
1.42
5 years
0.66
Extreme 0.6576
1.64
10 years
0.15
Extreme 0.15
1.64
More quotes

Managers and Directors - Pharming Group N.V.

Managers TitleAgeSince
Sijmen de Vries CEO
 Chief Executive Officer 65 08-10-12
Jeroen Wakkerman DFI
 Director of Finance/CFO 55 20-11-15
Anurag Relan CTO
 Chief Tech/Sci/R&D Officer 52 -
Members of the board TitleAgeSince
Mark Pykett BRD
 Director/Board Member 60 20-12-10
Leonard Kruimer BRD
 Director/Board Member 66 21-05-18
Sijmen de Vries CEO
 Chief Executive Officer 65 08-10-12
More insiders

ETFs positioned on Pharming Group N.V.

Name Weight AuM 1st Jan change Investor Rating
BMO MSCI GENOMIC INNOVATION INDEX ETF - CAD ETF BMO MSCI Genomic Innovation Index ETF - CAD
0.17% 2 M€ -.--%
BMO MSCI INNOVATION INDEX ETF - CAD ETF BMO MSCI Innovation Index ETF - CAD
0.05% 7 M€ -.--% -
SPDR MSCI WORLD SMALL CAP UCITS ETF - USD ETF SPDR MSCI World Small Cap UCITS ETF - USD
0.02% 746 M€ -.--% -
SIMPLIFY DEVELOPED EX-US PLUS DOWNSIDE CONVEXITY ETF - USD ETF Simplify Developed Ex-US Plus Downside Convexity ETF - USD
0.01% 10 M€ -3.35% -
More ETFs positioned on Pharming Group N.V.

Quotes

Date Price Change Volume
24-06-05 0.808 +2.54% 4 661 754
24-06-04 0.788 -3.19% 5,972,371
24-06-03 0.814 -0.79% 5,182,239
24-05-31 0.8205 -0.24% 21,900,890
24-05-30 0.8225 +1.54% 2,283,787

Real-time Euronext Amsterdam, June 05, 2024 at 11:35 am EDT

More quotes

Company Profile

Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The Group is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules, biologics, and gene therapies that are in early to late-stage development. Pharming Group N.V. serves patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia/Pacific.
Sector
Pharmaceuticals
Calendar
10:30am - Jefferies Global Healthcare Conference
More about the company

Income Statement Evolution

More financial data

Ratings for Pharming Group N.V.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.788 EUR
Average target price
1.917 EUR
Spread / Average Target
+143.23%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
PHARMING GROUP N.V. Stock Pharming Group N.V.
-21.63% 577M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+43.37% 750B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+34.11% 606B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.32% 356B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.97% 326B
ABBVIE INC. Stock AbbVie Inc.
+6.58% 286B
ASTRAZENECA PLC Stock AstraZeneca PLC
+18.08% 246B
ROCHE HOLDING AG Stock Roche Holding AG
-3.44% 213B
NOVARTIS AG Stock Novartis AG
+11.35% 213B
PFIZER, INC. Stock Pfizer, Inc.
+2.22% 167B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. PHARM Stock